PWMG
KRYS icon

Prestige Wealth Management Group’s Krystal Biotech KRYS Stock Holding History

Prestige Wealth Management Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49K Buy
4
+3
+300% +$896 ﹤0.01% 818
2026
Q1 		$259 Buy
+1
New +$266 ﹤0.01% 1051

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Prestige Wealth Management Group's KRYS Position: Q2 2026 in Review

Prestige Wealth Management Group increased its Krystal Biotech (KRYS) stake by 300% in Q2 2026, buying an estimated $896 and bringing the position to 4 shares worth $1.49K. The position accounts for ﹤0.01% of the portfolio, ranked #818.

Prestige Wealth Management Group first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Prestige Wealth Management Group held 4 shares of Krystal Biotech worth $1.49K as of Q2 2026.
  • Prestige Wealth Management Group bought 3 Krystal Biotech shares in Q2 2026, an estimated $896.
  • Krystal Biotech made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #818 holding.
  • Prestige Wealth Management Group first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.